News
Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF
A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of empagliflozin in patients with heart failure with a left ventricular ejection fraction (LV EF) > 40%. What insights does it provide regarding the impact on cardiovascular (CV) mortality or the need for hospitalization for heart failure (HHF) concerning left ventricular function?
EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?
At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and…
Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria
Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and…
EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?
What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of…
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on…
Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?
Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies…
MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information
How to offer a helping hand to patients amidst the flood of information and why is communication…
48 Tablets of Teriflunomide? Nothing Should Be Overdone! − Case Study
A case study published in the Journal of Clinical Pharmacy and Therapeutics describes an overdose…
Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor…
What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which…